A new peer review publication reaffirms the safety of Menicon Bloom Night™ lenses for slowing myopia progression in children

2024-07-24

Menicon Co., Ltd  is pleased to share the results of a new peer review paper that provides further support towards the safety of Menicon Bloom NightTM lenses for slowing myopia progression in children.1

Menicon Bloom NightTM contact lens is the overnight lens wear offering for myopia management included in Menicon BloomTM Myopia Control Management System, a holistic approach for myopia control management. Menicon Bloom NightTM is a CE-approved contact lens for the correction of refractive myopia and for myopia control, and is available in two different contact lens designs: Menicon Bloom Night™ and Menicon Bloom Night™ Toric.

The results from this new study, after being presented at various conferences worldwide, became available in full since July 12th, 2024 as ahead of print in Contact Lens and Anterior Eye, the peer review journal of the British Contact Lens Association. The study, entitled ‘The safety of orthokeratology contact lens wear in slowing the axial elongation of the eye in children’, is available for free via Open Access. By pooling together data from three prospective studies, this new paper was able to identify several key findings with regards the rate and reasons for discontinuations and adverse events as well as to the incidence of slit-lamp findings associated with overnight wear of Menicon Bloom NightTM lenses. More specifically, the paper reports that 19% of children wearing orthokeratology lenses discontinue lens wear, primarily due to lens fitting issues, such under-response to target myopic correction and poor centration, whereas 25% of children wearing spectacle lenses discontinue lens wear, primarily because they are seeking myopia control treatment. The study also found that around 10 to 20% of children wearing orthokeratology lenses will experience an adverse event over one year of lens wear (<10% for device-related adverse events alone), with the majority being non-significant and all adverse events resolving successfully, with no cases of any loss of best-corrected visual acuity. The incidence of slit-lamps findings grades ≥ 2 with overnight orthokeratology was found to be similar to that of no contact lens wear. To put the safety of the overnight orthokeratology into the context of overall contact lens wear, the study compared the incidence of anterior eye adverse events found with orthokeratology contact lens wear with that reported with daily wear soft contact lens types worn by children in other studies – this comparison shows that, although the incidence of adverse events with overnight orthokeratology is slightly higher compared to daily wear of soft contact lenses, both lens wear modalities show relatively similar safety profiles.

As many eye care practitionersare currently prescribing orthokeratology contact lenses such Menicon Bloom NightTM for slowing myopia progression in children,2 it was important to further understand the safety of this modality of lens wear, particularly because these lenses might be worn for many years - from childhood through adolescent years while myopia progresses to adulthood for conveniently correcting refractive error during the day without the need to wear glasses or contact lenses. This study comprehensibly reports on the safety issues that might be encountered when orthokeratology lenses are prescribed for slowing myopia progression in children, thus allowing eye care professionals to provide better advice to patients on this widely used treatment for myopia control.

Jacinto Santodomingo-Rubido, OD (EC), MSc, PhD, MCOptom, FBCLA, FAAO
The study’s main author and Menicon’s Clinical Affairs Manager and Senior Research Scientist


References

  1. Santodomingo-Rubido J, Cheung SW, Villa-Collar C; ROMIO/MCOS/TO-SEE Groups. The safety of orthokeratology contact lens wear in slowing the axial elongation of the eye in children. Cont Lens Anterior Eye. 2024 Jul 12:102258. doi: 10.1016/j.clae.2024.102258. Epub ahead of print. PMID: 39003152.
  2. Wolffsohn JS, Whayeb Y, Logan NS, Weng R; International Myopia Institute Ambassador Group*. IMI-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update. Invest Ophthalmol Vis Sci. 2023 May 1;64(6):6. doi: 10.1167/iovs.64.6.6. Erratum in: Invest Ophthalmol Vis Sci. 2023 May 1;64(5):12. doi: 10.1167/iovs.64.5.12. PMID: 37126357; PMCID: PMC10155870.